Suchergebnisse - "Safra, Tamar"

PubPharm (7)

1

Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitors

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Peleg Hasson, S. | Shachar, E. | Brezis, M. | +8

2

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4) : an international, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Lisyanskaya, A. | Fedenko, A. | +22

CommentIn: Lancet Oncol. 2022 Apr;23(4):440-441. - PMID 35298905

3

Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel

enthalten in: Cancer prevention research (Philadelphia, Pa.) | 2021

von Michaan, N. | Leshno, M. | Safra, T. | +3

4

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

enthalten in: British journal of cancer | 2018

von Friedlander, M. | Matulonis, U. | Gourley, C. | +18

5

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2017

von Kristeleit, R. | Shapiro, G. | Burris, H. | +17

6

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy : an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

enthalten in: The Lancet. Oncology | 2016

von Ledermann, J. | Harter, P. | Gourley, C. | +15

CommentIn: Lancet Oncol. 2016 Nov;17 (11):1474-1475. - PMID 27819228

7

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation : Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

enthalten in: Cancer | 2016

von Matulonis, U. | Harter, P. | Gourley, C. | +13

1
[1]